Literature DB >> 26011654

Efficient Synthesis and Biological Evaluation of 5'-GalNAc Conjugated Antisense Oligonucleotides.

Michael E Østergaard1, Jinghua Yu1, Garth A Kinberger1, W Brad Wan1, Michael T Migawa1, Guillermo Vasquez1, Karsten Schmidt1, Hans J Gaus1, Heather M Murray1, Audrey Low1, Eric E Swayze1, Thazha P Prakash1, Punit P Seth1.   

Abstract

Conjugation of triantennary N-acetyl galactosamine (GalNAc) to oligonucleotide therapeutics results in marked improvement in potency for reducing gene targets expressed in hepatocytes. In this report we describe a robust and efficient solution-phase conjugation strategy to attach triantennary GalNAc clusters (mol. wt. ∼2000) activated as PFP (pentafluorophenyl) esters onto 5'-hexylamino modified antisense oligonucleotides (5'-HA ASOs, mol. wt. ∼8000 Da). The conjugation reaction is efficient and was used to prepare GalNAc conjugated ASOs from milligram to multigram scale. The solution phase method avoids loading of GalNAc clusters onto solid-support for automated synthesis and will facilitate evaluation of GalNAc clusters for structure activity relationship (SAR) studies. Furthermore, we show that transfer of the GalNAc cluster from the 3'-end of an ASO to the 5'-end results in improved potency in cells and animals.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26011654     DOI: 10.1021/acs.bioconjchem.5b00265

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  24 in total

Review 1.  Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

Authors:  Alexandre J Debacker; Jon Voutila; Matthew Catley; David Blakey; Nagy Habib
Journal:  Mol Ther       Date:  2020-06-17       Impact factor: 11.454

2.  Modifying a Commonly Expressed Endocytic Receptor Retargets Nanoparticles in Vivo.

Authors:  Cory D Sago; Melissa P Lokugamage; Gwyneth N Lando; Naima Djeddar; Nirav N Shah; Chris Syed; Anton V Bryksin; James E Dahlman
Journal:  Nano Lett       Date:  2018-09-20       Impact factor: 11.189

3.  Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.

Authors:  Samantha M Sarett; Thomas A Werfel; Linus Lee; Meredith A Jackson; Kameron V Kilchrist; Dana Brantley-Sieders; Craig L Duvall
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

Review 4.  Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.

Authors:  Colton M Miller; Michael Tanowitz; Aaron J Donner; Thazha P Prakash; Eric E Swayze; Edward N Harris; Punit P Seth
Journal:  Nucleic Acid Ther       Date:  2018-02-09       Impact factor: 5.486

5.  Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides.

Authors:  Naoki Iwamoto; David C D Butler; Nenad Svrzikapa; Susovan Mohapatra; Ivan Zlatev; Dinah W Y Sah; Stephany M Standley; Genliang Lu; Luciano H Apponi; Maria Frank-Kamenetsky; Jason Jingxin Zhang; Chandra Vargeese; Gregory L Verdine
Journal:  Nat Biotechnol       Date:  2017-08-21       Impact factor: 54.908

6.  Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity.

Authors:  Ken Yamada; Samuel Hildebrand; Sarah M Davis; Rachael Miller; Faith Conroy; Ellen Sapp; Jillian Caiazzi; Julia F Alterman; Loic Roux; Dimas Echeverria; Matthew R Hassler; Edith L Pfister; Marian DiFiglia; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2021-12-02       Impact factor: 16.971

Review 7.  Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes.

Authors:  Erika Dosekova; Jaroslav Filip; Tomas Bertok; Peter Both; Peter Kasak; Jan Tkac
Journal:  Med Res Rev       Date:  2016-11-15       Impact factor: 12.944

8.  Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides.

Authors:  Tsuyoshi Yamamoto; Yahiro Mukai; Fumito Wada; Chisato Terada; Yukina Kayaba; Kaho Oh; Asako Yamayoshi; Satoshi Obika; Mariko Harada-Shiba
Journal:  Pharmaceutics       Date:  2021-05-31       Impact factor: 6.321

Review 9.  Development of Antisense Drugs for Dyslipidemia.

Authors:  Tsuyoshi Yamamoto; Fumito Wada; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2016-07-27       Impact factor: 4.928

Review 10.  Noncoding RNA therapeutics - challenges and potential solutions.

Authors:  Melanie Winkle; Sherien M El-Daly; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2021-06-18       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.